Company Encyclopedia
View More
name
InMed Pharmaceuticals
INM.US
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.
4.715 T
INM.USMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking105/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-82.17%E
    • Profit Margin-171.13%E
    • Gross Margin35.99%C
  • Growth ScoreC
    • Revenue YoY-3.27%D
    • Net Profit YoY-20.46%D
    • Total Assets YoY27.67%A
    • Net Assets YoY38.06%A
  • Cash ScoreD
    • Cash Flow Margin-58.43%D
    • OCF YoY-3.27%D
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreA
    • Gearing Ratio13.25%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Q4 Virtual Investor Summit Presentations Now Available On Demand

    Investor Summit Group announces that presentations from the Q4 Virtual Investor Summit are now available for on-demand viewing. Held on December 9, the event featured microcap companies sharing updates and strategic outlooks. Investors can access company presentations at their convenience, exploring key insights and opportunities. The summit included companies like InMed Pharmaceuticals, Gelteq Limited, and Faraday Future Intelligent Electric Inc. For more information, visit the Investor Summit Group website.

    Acceswire·
    US
    FFAI
    -3.57%
    US
    INM
    -2.46%
    US
    FFIE
    0.00%
    Acceswire·
    US
    FFAI
    -3.57%
    US
    INM
    -2.46%
    US
    FFIE
    0.00%

    InMed Shareholders Approve Directors and Equity Financing Flexibility

    InMed Pharmaceuticals held its 2025 Annual General and Special Meeting, where shareholders re-elected five directors and approved CBIZ CPAs P.C. as auditor. They also endorsed potential issuance of 20% or more of shares under a Standby Equity Purchase Agreement, indicating support for the board and flexible equity financing. The meeting's results were reported on SEDAR. Analysts rate INM stock as a 'Sell' with a $2.50 target, citing financial performance concerns despite a recent $5M private placement.

    Tip Ranks·
    US
    INM
    -2.46%
    Tip Ranks·
    US
    INM
    -2.46%

    InMed Announces Results of 2025 Annual General and Special Meeting | INM Stock News

    InMed Pharmaceuticals Inc. announced the results of its 2025 annual general and special meeting. Shareholders voted on various matters, including the election of the board of directors and the approval of CBIZ CPAs P.C. as auditors. They also approved the potential issuance of 20% or more of the company's common shares under the Standby Equity Purchase Agreement. Approximately 35.43% of the company's shares were represented at the meeting. InMed focuses on developing small molecule drug candidates for diseases with high unmet needs.

    StockTitan·
    US
    INM
    -2.46%
    StockTitan·
    US
    INM
    -2.46%

    ADVISORY-Dated alerts on InMed Pharmaceuticals withdrawn

    Alerts published on InMed Pharmaceuticalsexpecting the H.R. 5371 Act to have a negative impact on its unit Baymedica were dated and have been withdrawn. There will be no substitute. STORY_NUMBER:nFWN3XL0AQ STORY_DATE: December 15, 2025 STORY_TIME: 02:37 PM GMT

    Reuters·
    US
    INM
    -2.46%
    Reuters·
    US
    INM
    -2.46%

    InMed Faces Challenges from New U.S. Legislation

    InMed Pharmaceuticals announced that the H.R. 5371 Act may negatively impact its subsidiary, BayMedica Inc., by restricting certain commercial activities related to rare cannabinoids. However, InMed's core pharmaceutical programs remain unaffected. Analysts rate INM stock as a Sell with a $2.50 target, citing financial performance concerns. Despite a recent $5M private placement, operational losses and negative cash flows pose risks. InMed focuses on developing drug candidates targeting CB1/CB2 receptors for Alzheimer's and other conditions.

    Tip Ranks·
    US
    INM
    -2.46%
    Tip Ranks·
    US
    INM
    -2.46%
    © 2025 Longbridge｜Disclaimer